ARIKACE™ Demonstrates Sustained Benefit In Multiple Studies And Over Multiple Cycles

tD33NAt

Active member
Joined
Mar 24, 2008
Messages
12,519
Reaction score
0
Points
36
Transave, Inc., reported positive clinical trial results on its lead investigational drug, ARIKACE™ (liposomal amikacin for inhalation), an antibiotic that is entering Phase III development for the treatment of chronic lung infections. The results demonstrate significant clinical benefit and complete the company's Phase II program for the treatment of lung infections due to the bacterium, Pseudomonas aeruginosa in cystic fibrosis (CF) patients...


aCmJe1UMPjo


More...
 
Back
Top